42,000 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Smith Group Asset Management LLC

Smith Group Asset Management LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 42,000 shares of the medical device company’s stock, valued at approximately $3,266,000.

A number of other hedge funds have also modified their holdings of the company. B. Riley Wealth Advisors Inc. raised its position in shares of DexCom by 4.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after purchasing an additional 162 shares during the period. Crossmark Global Holdings Inc. increased its stake in DexCom by 1.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after buying an additional 182 shares in the last quarter. Riverview Trust Co raised its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares in the last quarter. Finally, Koa Wealth Management LLC boosted its stake in shares of DexCom by 7.7% in the third quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock worth $253,000 after acquiring an additional 270 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $88.30 on Wednesday. The business’s 50 day moving average price is $79.73 and its 200-day moving average price is $76.70. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a market cap of $34.49 billion, a P/E ratio of 52.87, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent analyst reports. Sanford C. Bernstein lifted their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Canaccord Genuity Group boosted their price target on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.